Hypoactive Sexual Desire Disorder in Women: Treatment Options Beyond Testosterone and Approaches to Communicating with Patients on Sexual Health

@article{Lodise2013HypoactiveSD,
  title={Hypoactive Sexual Desire Disorder in Women: Treatment Options Beyond Testosterone and Approaches to Communicating with Patients on Sexual Health},
  author={Nicole M. Lodise},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2013},
  volume={33}
}
  • Nicole M. Lodise
  • Published 1 April 2013
  • Medicine
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Hypoactive sexual desire disorder (HSDD) affects nearly 1 in 10 women. Thus, it is essential for pharmacists and other health care providers to be comfortable when discussing a patient's sexual health to ensure appropriate triage so that the specific causes of HSDD can be identified and potential recommendations provided. HSDD is defined as the absence or deficiency of sexual interest and/or desire, leading to significant distress and interpersonal difficulties. As health care providers… 
Female Sexual Dysfunction: Pharmacologic and Therapeutic Interventions.
TLDR
Female sexual dysfunction is often overlooked in clinical practice; however, there are effective medical and psychological options for management.
Advances in pharmacotherapy for treating female sexual dysfunction
TLDR
The paper reports the most recent advances in pharmacotherapy for women taking into account the biopsychosocial model and discusses the potential use of on-demand combined hormonal (testosterone) and non-hormonal (buspirone or sildenafil) treatments to address possible neurophysiological profiles of women.
A practical guide to female sexual dysfunction: An evidence-based review for physicians in Canada.
  • Y. Krakowsky, E. Grober
  • Medicine, Psychology
    Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • 2018
TLDR
There are evidence-based diagnostic and therapeutic approaches to FSD that can be broadly applied by Canadian physicians to improve access to female sexual medicine in Canada.
Flibanserin- A Novel drug for Hypoactive Sexual Desire Disorder
TLDR
Flibanserin, a novel, non-hormonal, multifunctional serotonin agonist antagonist (MSAA) was used in most of the pre-menopausal women diagnosed with Hypoactive Sexual Desire Disorder (HSDD) but its approval also faced a little scepticism.
A Practical Approach to Managing Hypoactive Sexual Desire Disorder in Women with Diabetes
TLDR
Flibanserin is the only therapy approved by the US Food and Drug Administration for treating acquired, generalized HSDD in premenopausal women and may require a multidisciplinary approach for optimal management.
Sex and Pharmacological Sexual Enhancement
TLDR
There is a growing body of literature describing pharmacological interventions, but in many cases their utility is hard to establish due to placebo responses, side effect profiles, and negative impact of comorbidities.
Flibanserin: A controversial drug for female hypoactive sexual desire disorder
TLDR
A novel multifunctional serotonin agonist and antagonist, flibanserin, has been shown to be efficacious in treating HSDD but with a rather tenacious side effect profile.
Systematic Review of l-Arginine for the Treatment of Hypoactive Sexual Desire Disorder and Related Conditions in Women
TLDR
It is found that combination products containing l-arginine in the form of ArginMax or Lady Prelox may be considered for the treatment of HSDD and related conditions in women regardless of age.
Flibanserin (Addyi)
TLDR
Female sexual interest/arousal disorder (FSIAD) is a newly appeared clinical diagnosis that appears in the Diagnostic and Statistical Manual of Mental Disorders, fi fth edition (DSM-5).
Dysfunction of Sexual and Accessory Sex Organs
TLDR
The issue of sexual dysfunction in diabetes is not limited to purveying prescriptions for drugs that are of help in this situation but the understanding of nondrug issues is also essential to deal with those not infrequent unsatisfactory results after drug treatment.
...
1
2
3
...

References

SHOWING 1-10 OF 72 REFERENCES
Testosterone Supplementation for Hypoactive Sexual Desire Disorder in Women
TLDR
Although studies have shown some benefit with testosterone supplementation in women with HSDD, conflicting evidence and debate regarding the clinical efficacy of testosterone remain.
Flibanserin: A Potential Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Women
TLDR
An overview of the pharmacology, clinical efficacy and safety of flibanserin is presented, a 5-HT1A agonist/5-HT2A antagonist that is under investigation as a treatment for HSDD in women.
Physician attitudes regarding hypoactive sexual desire disorder in a primary care clinic: a pilot study.
TLDR
There is an opportunity to improve patient care and life satisfaction by offering physicians training on diagnosis and management of hypoactive sexual desire disorder (HSDD) in the primary care setting.
Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study.
TLDR
In premenopausal women with HSDD, flibanserin 50 mg and 100’mg once daily at bedtime were well tolerated and associated with statistically significant improvements in SSE, sexual desire, and overall sexual function, and reduction of sexual distress, vs. placebo.
Medications that may contribute to sexual disorders. A guide to assessment and treatment in family practice.
TLDR
Basic guidelines designed to assist physicians in evaluating the effects of medications and other substances on sexual function are provided and lists of medications known or suspected to have adverse effects onSexual function are included.
Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study.
TLDR
In premenopausal women with HSDD, flibanserin 100 mg once daily was well tolerated and associated with statistically significant improvements in SSE, sexual desire, sexual function, and decrease in sexual distress vs. placebo.
Female sexuality and sexual dysfunction: are we stuck on the learning curve?
TLDR
Healthcare professionals are aware of the high prevalence of FSDs but infrequently initiate a discussion of sexual function with their female patients or conduct a comprehensive evaluation for FSDe, which are under-recognized and undertreated.
From whence comes HSDD?
  • S. Parish
  • Psychology, Medicine
    The Journal of family practice
  • 2009
TLDR
An understanding of the definitions of FSD and HSDD, their prevalence in various subpopulations of women, and their impact on quality of life can increase awareness of the importance of these disorders and help family physicians appreciate the place of H SDD within the spectrum of F SD and become better equipped to recognize this disorder in clinical practice.
Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD).
TLDR
The Decreased Sexual Desire Screener is a sensitive and specific brief diagnostic instrument for generalized acquired HSDD in women that is quick and easy to use.
Effect of Sildenafil on Subjective and Physiologic Parameters of the Female Sexual Response in Women with Sexual Arousal Disorder
TLDR
Sildenafil appears to significantly improve both subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder (SAD).
...
1
2
3
4
5
...